NYSE:PAAS - New York Stock Exchange, Inc. - CA6979001089 - Common Stock - Currency: USD
Wheaton Precious Metals' Q1 results are anticipated to reflect lower year-over-year sales volumes offset by higher prices for gold and silver.
BG's Q1 results are anticipated to reflect weak year-over-year performances in its segments and the impacts of the divestiture of the Sugar and Bioenergy segment.
Hecla Mining (HL) delivered earnings and revenue surprises of 33.33% and 10.61%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: HL
In the closing of the recent trading day, Pan American Silver (PAAS) stood at $25.18, denoting a -0.36% change from the preceding trading day.
Pan American Silver (PAAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In the latest trading session, Pan American Silver (PAAS) closed at $26.01, marking a +1.29% move from the previous day.
Gold surged to fresh all-time highs on Monday, with bullion jumping 2.5% to $3,410 per ounce by 11:20 a.m. ET, as mounting distrust in U.S. financial assets and inflation fears drive a flight to safety unlike anything seen since the global debt crises of the early 2010s.
Scotiabank analyst Eric Winmill raised the firm’s price target on New Gold (NGD) to $4.75 from $4.25 and keeps an Outperform rating on the shares. The firm has a positive outlook on the Gold & Precious Minerals sector, the analyst tells investors. The firm expects consolidation to continue into 2025, with heightened marketing & acquisition activity enabling companies to optimize their asset portfolios. Published first on TheFly – the ultimate source for real-time, market-moving breaking financia
Scotiabank raised the firm’s price target on Pan American Silver (PAAS) to $32 from $28.50 and keeps a Sector Perform rating on the shares. The firm has a positive outlook on the Gold & Precious Minerals sector, the analyst tells investors. The firm expects consolidation to continue into 2025, with heightened marketing & acquisition activity enabling companies to optimize their asset portfolios. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news.
BofA analyst Michael Ryskin lowered the firm’s price target on Mettler-Toledo (MTD) to $1,250 from $1,500 and keeps a Neutral rating on the shares. Sentiment for Life Sciences and Diagnostic Tools and Contract Research Organizations is “particularly negative” heading into earnings given that these companies “sit at the intersection of a number of policy changes from the Trump Administration,” including headwinds from NIH budget cuts and global tariffs, as well as broader macro concerns, especial
European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S. investment. The $200 billion pharma company intends to invest $23 billion in U.S.-based manufacturing to conduct research and development and produce all its major drugs stateside. Judging by Novartis’ stock performance in the days following the news, the market signaled its approval. Donald Trump is likely to be delighted, too. Novartis’ latest move is a reactiv
Mentions: PAAS.CA
Explore three leveraged gold ETFs—GDXU, NUGT, and JNUG—as investors seek safe havens amid market turmoil. Learn how each fund plays gold’s 2025 surge.
Among ETFs with over $1 billion in assets, three funds are leading the pack when it comes to returns in 2025. Precious metals are what they have in common.
Mentions: PAAS.CA
PAAS earnings call for the period ending December 31, 2024.
Mentions: PAAS.CA
Mentions: PAAS.CA
Mentions: PAAS.CA
Mentions: PAAS.CA
PAAS earnings call for the period ending September 30, 2024.
Mentions: PAAS.CA
Mentions: PAAS.CA
/PRNewswire/ - Metalla Royalty & Streaming Ltd. ("Metalla") (NYSE American: MTA) (TSXV: MTA) is pleased to report select portfolio updates: Gosselin (1.35%...
Mentions: IAG
Mentions: PAAS.CA